DEA Extends Telemedicine Flexibilities for Controlled Medications
Summary
The DEA, in conjunction with HHS, has extended current telemedicine flexibilities for prescribing controlled medications through December 31, 2026. This allows DEA-registered practitioners to remotely prescribe Schedule II-V controlled medications, including certain narcotic medications for opioid use disorder treatment, without a prior in-person evaluation.
What changed
The Drug Enforcement Administration (DEA), in coordination with the Department of Health and Human Services (HHS), has issued a fourth temporary extension of COVID-19 telemedicine flexibilities, pushing the deadline to December 31, 2026. This extension permits DEA-registered practitioners to prescribe Schedule II-V controlled medications, including Schedule III-V narcotic controlled medications for opioid use disorder treatment, via audio-video or audio-only telemedicine encounters without a prior in-person medical evaluation, provided all other DEA and applicable federal/state laws are met.
This extension is critical for ensuring continued patient access to care, particularly for those relying on telemedicine for controlled substance prescriptions. Healthcare providers must ensure that all prescriptions issued under these flexibilities continue to comply with existing DEA guidance, regulations, and federal and state laws. The full details of the extension are available in the DEA's press release and have been published in the Federal Register.
What to do next
- Ensure all telemedicine prescriptions for controlled medications comply with DEA guidance and federal/state law.
- Note the extended deadline of December 31, 2026, for these flexibilities.
Archived snapshot
Mar 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care - Current Topics
DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care
By k Capehart 1/3/2026 The DEA, along with the Department of Health and Human Services has issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, extending the current telemedicine flexibilities through December 31, 2026.
Under these telemedicine flexibilities, DEA-registered practitioners are permitted to remotely prescribe Schedule II-V controlled medications via audio-video telemedicine encounters, including Schedule III-V narcotic controlled medications approved by the Food and Drug Administration (FDA) for maintenance and withdrawal management treatment of opioid use disorder via audio-only telemedicine encounters, without having ever conducted an in-person medical evaluation, provided that such prescriptions otherwise comply with the requirements outlined in DEA guidance documents, DEA regulations, and applicable federal and state law.
The entire statement can be found here. It is published in the Federal Register here.
Related changes
Get daily alerts for WV Board of Pharmacy
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from State BOP.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when WV Board of Pharmacy publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.